Edition:
United States

Galena Biopharma Inc (GALE.OQ)

GALE.OQ on NASDAQ Stock Exchange Capital Market

2.58USD
10:59am EST
Change (% chg)

$-0.03 (-1.15%)
Prev Close
$2.61
Open
$2.60
Day's High
$2.61
Day's Low
$2.53
Volume
15,872
Avg. Vol
38,494
52-wk High
$49.80
52-wk Low
$2.52

GALE.OQ

Chart for GALE.OQ

About

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S),... (more)

Overall

Beta: 2.90
Market Cap(Mil.): $28.32
Shares Outstanding(Mil.): 10.85
Dividend: --
Yield (%): --

Financials

  GALE.OQ Industry Sector
P/E (TTM): -- 30.04 30.65
EPS (TTM): -2.32 -- --
ROI: -52.64 15.86 15.23
ROE: -70.89 16.96 16.56

BRIEF-RXi Pharmaceuticals reports Q3 financial results

* RXi Pharmaceuticals Corp - Net loss for quarter ended september 30, 2016 was $2.2 million, compared with $2.5 million for quarter ended September 30, 2015

Nov 10 2016

BRIEF-Galena Biopharma Q3 loss per share $0.03

* Galena biopharma reports third quarter 2016 financial results and provides a corporate update

Nov 09 2016

BRIEF-Galena Biopharma appoints Stephen Ghiglieri as CFO

* Galena biopharma - Stephen Ghiglieri has been appointed as company's executive vice president and chief financial officer, effective immediately

Nov 03 2016

BRIEF-Galena Biopharma announces reverse stock split

* Galena Biopharma Inc - board of directors approved a reverse stock split of its shares of common stock at a ratio of 1-for-20

Oct 31 2016

BRIEF-RXI Pharmaceuticals files for common stock offering of up to $20.7 mln

* Files for common stock offering of up to $20.7 million - SEC filng Source: (http://bit.ly/2dVTOow) Further company coverage:

Oct 21 2016

BRIEF-RXi Pharmaceuticals plans to conduct securities offering

* RXi Pharmaceuticals -to use net proceeds to enable smooth integration of Mirimmune into RXi in event RXi exercises its option to acquire Mirimmune Inc Source text for Eikon: Further company coverage:

Oct 12 2016

BRIEF-RXi Pharmaceuticals enters into exclusive option agreement to acquire Mirimmune Inc

* RXi Pharmaceuticals enters into exclusive option agreement to acquire Mirimmune Inc

Oct 12 2016

BRIEF-Galena Biopharma says combination of trastuzumab and NeuVax in HER2 low-expressing patients is well-tolerated

* Galena Biopharma Inc - combination of trastuzumab and neuvax in HER2 low-expressing (le) patients is well-tolerated

Oct 10 2016

CORRECTED-BRIEF-Galena Biopharma files registration statement related to previously-issued warrants (Sept. 30)

* Files registration statement for shares of common stock upon exercise of previously-issued warrants for sale by selling stockholders of up to 14 million shares Source text for Eikon: (http://bit.ly/2dr9LGs) Further company coverage:

Oct 03 2016

BRIEF-Galena biopharma - currently enrolling HER2 1+ and 2+ node positive

* Currently enrolling HER2 1+ and 2+ node positive, high-risk node negative patients to study NeuVax in combination with trastuzumab Source text for Eikon: Further company coverage:

Sep 29 2016

Competitors

Earnings vs. Estimates